Premium
Analysis of JAK2 V617F mutation in Chinese patients with myeloproliferative disorders
Author(s) -
Chen Suning,
Fei Hairong,
Zhang Ri,
Xue Yongquan,
Pan Jinlan,
Wu Yafang,
Ceng Jiang
Publication year - 2007
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20872
Subject(s) - essential thrombocythemia , myelofibrosis , jak2 v617f , polycythemia vera , mutation , point mutation , myeloid , medicine , myeloproliferative disorders , polymerase chain reaction , gastroenterology , biology , bone marrow , genetics , gene
It is now well‐recognized that the activating JAK2 V617F mutation occurs in the majority of patients with polycythemia vera (PV) and approximately half of those with either essential thrombocythemia (ET) or myelofibrosis with myeloid metaplasia (MMM). Here we analyzed JAK2 V617F mutation in 137 Chinese patients with myeloproliferative disorders by allele‐specific polymerase chain reaction (PCR). DNA was extracted from methanol/acetic acid‐fixed cells that had been routinely prepared for cytogenetic analysis. A single point mutation (Val617Phe) was identified in JAK2 in 42 (73.7%) of 57 patients with PV, 40 (58.8%) of 68 with ET, and eight (66.7%) of 12 with MMM. Am. J. Hematol., 2007. © 2007 Wiley‐Liss, Inc.